Page 167 - 2018_09-Mondo

Platelet dysfunction in chemotherapy
ments-and-side-effects/treatment-types/ chemotherapy/how-chemotherapy-drugs- work.html. Last accessed November 2017.
20. CBO. Blood transfusion guidelines- the Netherlands. 2011.
21. Smeets EF, Heemskerk JW, Comfurius P, Bevers EM, Zwaal RF. Thapsigargin ampli- fies the platelet procoagulant response caused by thrombin. Thromb Haemost. 1993;70(6):1024-1029.
22. Vogler M, Hamali HA, Sun XM, et al. BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelets activation. Blood. 2011;117(26):7145-7154.
23. Solari FA, Mattheij NJ, Burkhart JM, et al. Combined quantification of the global pro- teome, phosphoproteome, and proteolytic cleavage to characterize altered platelet functions in the human Scott syndrome. Mol Cell Proteomics. 2016;15(10):3154- 3169.
24. Kramer PA, Ravi S, Chacko B, Johnson MS, Darley-Usmar VM. A review of the mito- chondrial and glycolytic metabolism in human platelets and leukocytes: Implications for their use as bioenergetic biomarkers. Redox Biol. 2014;2:206-210.
25. Mattheij NJ, Gilio K, van Kruchten R, et al. Dual mechanism of integrin aiibb3 closure in procoagulant platelets. J Biol Chem. 2013;288(19):13325-13336.
26. van Kruchten R, Mattheij NJA, Saunders C, et al. Both TMEM16F-dependent and TMEM16F-independent pathways con- tribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood. 2013;121(10):1850-1857.
27. Lanza IR, Nair KS. Mitochondrial metabolic function assessed in vivo and in vitro. Curr Opin Clin Nutr Metab Care. 2010;13(5):511- 517.
28. Larsen S, Nielsen J, Hansen CN, et al. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol. 2012;590(14):3349-3360.
29. Gilliam LAA, Fisher-Wellman KH, Lin CT, et al. The anticancer agent doxorubicin dis- rupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic Biol Med. 2013;65:988-996.
30. Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond symptomatic relief for chemotherapy-induced peripheral neuropa- thy: Targeting the source. Cancer. 2018;Epub ahead of print.
31. Zeuner A, Signore M, Martinetti D, et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be res- cued by stem cell factor. Cancer Res. 2007; 67(10):4767-4773.
32. Riedl J, Kaider A, Marosi C, et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous throm- boembolism and poor prognosis. Thromb Haemost. 2017;117(1):90-98.
33. Baaten CC, Ten Cate H, van der Meijden PE, Heemskerk JW. Platelet populations and priming in hematological diseases. Blood Rev. 2017;31(6):389-399.
34. Sorensen JC, Cheregi BD, Timpani CA, et al. Mitochondria: inadvertent targets in chemotherapy-induced skeletal muscle toxi- city and wasting? ' Cancer Chemother Pharmacol. 2016;78(4):673-683.
35. Gouspillou G, Scheede-Bergdahl C, Spendiff S, et al. Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle. Sci Rep. 2015;5:8717.
36. Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617-630.
38. Prasad SB, Rosangkima G, Nicol BM. Cyclophosphamide and ascorbic acid-medi- ated ultrastructural and biochemical changes in Dalton's lymphoma cells in vivo. Eur J Pharmacol. 2010;645(1-3):47-54.
39. Kang PT, Chen CL, Ren P, Guarini G, Chen YR. BCNU-induced gR2 defect mediates S- glutathionylation of complex I and respira- tory uncoupling in myocardium. Biochem Pharmacol. 2014;89(4):490-502.
40. Corona de la Peña N, Gutiérrez-Aguilar M, Hernández-Reséndiz I, Marín-Hernández Á, Rodríguez-Enríguez S. Glycoprotein Ib acti- vation by thrombin stimulates the energy metabolism in human platelets. PLoS One. 2017;12(8):e0182374.
41. Bergmeier W, Piffath CL, Cheng G, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res. 2004;95(7):677-683.
42. Zhang Q, Dong T, Li P, Wu MX. Noninvasive low-level laser therapy for thrombocytopenia. Sci Transl Med. 2016; 8(349):349ra101.
43. Huijskens MJ, Wodzig WK, Walczak M, Germeraad WT, Bos GM. Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol. 2016;6:8-10.
44. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693.
45. Hoffbrand AV, Moss PAH. Essential Haematology. 6th ed: Wiley-Blackwell; 2011.
46. Giordano P, Molinari AC, Del Vecchio GC, et al. Prospective study of hemostatic alter- ations in children with acute lymphoblastic leukemia. Am J Hematol. 2010;85(5):325-
37. al-Nasser IA. In vivo prevention of cyclophosphamide-induced Ca2+ depend- 330.
ent damage of rat heart and liver mitochon- dria by cyclosporin A. Comp Biochem Physiol A Mol Integr Physiol. 1998; 121(3):209-214.
47. Briggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet frac- tion (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004; 126(1):93-99.
haematologica | 2018; 103(9)
1567